---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015573"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:41:10.418657+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma Q2 revenue $28.1M; Astellas collaboration adds $90M cash, cash runway into H1 2024

## Summary
- Q2 revenue $28.1M (flat YoY); operating expenses $47.5M vs $37.9M in Q2 2021.
- Cash $191.6M at June 30; plus $90M Astellas upfront in July, providing runway into H1 2024.
- Entered iADC collaboration with Astellas for up to 3 targets; $90M upfront, $422.5M milestones per candidate.
- Merck triggered $10M milestone upon first patient dosed in Phase 1 of MK-1484 (IL-2 agonist).
- FDA signaled accelerated approval pathway possible for STRO-002 in platinum-resistant ovarian cancer; data expected H2 2022.

## SEC filing metadata
- accession: 0000950170-22-015573
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017022015573/0000950170-22-015573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017022015573/stro-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015573
- JSON: https://secwatch.observer/filing/0000950170-22-015573.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.